Inovio Kicks Off 2nd Stage of Phase 1 Human Trials of Ebola DNA Vaccine; J. Joseph Kim Comments
Inovio Pharmaceuticals has begun to enroll 125 individuals for the second stage of the Phase 1 clinical trial of its Ebola DNA vaccine candidate in an effort to evaluate how the vaccine generates immune responses. Inovio tested the INO-4212 vaccine in 75 healthy volunteers during the first clinical trial’s initial stage and found that 100 percent […] More